BRPI0615787B8 - derivados de piridina e seu uso no tratamento de distúrbios psicóticos - Google Patents
derivados de piridina e seu uso no tratamento de distúrbios psicóticosInfo
- Publication number
- BRPI0615787B8 BRPI0615787B8 BRPI0615787A BRPI0615787A BRPI0615787B8 BR PI0615787 B8 BRPI0615787 B8 BR PI0615787B8 BR PI0615787 A BRPI0615787 A BR PI0615787A BR PI0615787 A BRPI0615787 A BR PI0615787A BR PI0615787 B8 BRPI0615787 B8 BR PI0615787B8
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- heterocyclyl
- aryl
- heteroaryl
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Reproductive Health (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0518472A GB0518472D0 (en) | 2005-09-09 | 2005-09-09 | Novel compounds |
| GB0518472.6 | 2005-09-09 | ||
| GB0611153A GB0611153D0 (en) | 2006-06-06 | 2006-06-06 | Novel compounds |
| GB0611153.8 | 2006-06-06 | ||
| PCT/EP2006/008845 WO2007028654A1 (en) | 2005-09-09 | 2006-09-07 | Pyridine derivatives and their use in the treatment of psychotic disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0615787A2 BRPI0615787A2 (pt) | 2009-06-16 |
| BRPI0615787B1 BRPI0615787B1 (pt) | 2020-08-11 |
| BRPI0615787B8 true BRPI0615787B8 (pt) | 2021-05-25 |
Family
ID=37546936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0615787A BRPI0615787B8 (pt) | 2005-09-09 | 2006-09-07 | derivados de piridina e seu uso no tratamento de distúrbios psicóticos |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US7683056B2 (enExample) |
| EP (2) | EP2336136A1 (enExample) |
| JP (1) | JP5121716B2 (enExample) |
| KR (1) | KR101292348B1 (enExample) |
| CN (1) | CN101305011B (enExample) |
| AR (1) | AR058805A1 (enExample) |
| AT (1) | ATE505472T1 (enExample) |
| AU (1) | AU2006289281B2 (enExample) |
| BR (1) | BRPI0615787B8 (enExample) |
| CA (1) | CA2621564C (enExample) |
| CR (1) | CR9847A (enExample) |
| CY (1) | CY1111907T1 (enExample) |
| DE (1) | DE602006021323D1 (enExample) |
| DK (1) | DK1928886T3 (enExample) |
| EA (1) | EA013909B1 (enExample) |
| HR (1) | HRP20110457T1 (enExample) |
| IL (1) | IL189578A (enExample) |
| JO (1) | JO2722B1 (enExample) |
| MA (1) | MA29780B1 (enExample) |
| MY (1) | MY145713A (enExample) |
| NO (1) | NO340921B1 (enExample) |
| NZ (1) | NZ565983A (enExample) |
| PE (1) | PE20070614A1 (enExample) |
| PL (1) | PL1928886T3 (enExample) |
| PT (1) | PT1928886E (enExample) |
| SI (1) | SI1928886T1 (enExample) |
| TW (1) | TWI378101B (enExample) |
| WO (1) | WO2007028654A1 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007039123A2 (en) * | 2005-09-22 | 2007-04-12 | Smithkline Beecham Corporation | Combination therapy comprising an nk-3 antagonist and an antipsychotic agent |
| ATE472529T1 (de) * | 2005-10-10 | 2010-07-15 | Glaxo Group Ltd | Prolinamidderivate als natriumkanalmodulatoren |
| TW200730494A (en) * | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
| EP2774925B1 (en) | 2005-11-08 | 2016-12-28 | Vertex Pharmaceuticals Incorporated | Heterocyclic modulators of ATP-binding cassette transporters |
| US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
| JP2010516731A (ja) | 2007-01-24 | 2010-05-20 | グラクソ グループ リミテッド | ２−メトキシ−５−（５−トリフルオロメチル−テトラゾール−１−イル）−ベンジル］−（２ｓ−フェニル−ピペリジン−３ｓ−イル）−アミンを含む医薬組成物 |
| KR20100007956A (ko) | 2007-05-03 | 2010-01-22 | 화이자 리미티드 | 나트륨 채널 조절제로서의 2-피리딘 카복스아마이드 유도체 |
| WO2008141119A2 (en) | 2007-05-09 | 2008-11-20 | Vertex Pharmaceuticals Incorporated | Modulators of cftr |
| HUE031913T2 (en) | 2007-12-07 | 2017-08-28 | Vertex Pharma | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
| PL2231606T3 (pl) | 2007-12-07 | 2013-07-31 | Vertex Pharma | Sposoby wytwarzania kwasów cykloalkilokarboksyamidopirydynobenzoesowych |
| ES2454366T3 (es) * | 2008-02-22 | 2014-04-10 | Neurotune Ag | Compuestos bicíclicos que contienen nitrógeno activos en afecciones de dolor crónico |
| JP5523352B2 (ja) | 2008-02-28 | 2014-06-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｃｆｔｒ修飾因子としてのへテロアリール誘導体 |
| FR2928150A1 (fr) | 2008-02-29 | 2009-09-04 | Vetoquinol Sa Sa | Nouveaux derives 7-substitues de 3-carboxy-oxadiazino-quinolones, leur preparation et leur application comme anti-bacteriens |
| WO2009119528A1 (ja) * | 2008-03-24 | 2009-10-01 | 武田薬品工業株式会社 | 複素環化合物 |
| GB0808747D0 (en) | 2008-05-14 | 2008-06-18 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
| EP2145891A1 (en) | 2008-07-09 | 2010-01-20 | Vetoquinol S.A. | 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials |
| GB0814340D0 (en) * | 2008-08-05 | 2008-09-10 | Smithkline Beecham Corp | Anhydrous crystol form fo a pyridine derivative |
| AR077688A1 (es) | 2009-08-04 | 2011-09-14 | Takeda Pharmaceutical | Compuestos heterociclicos, utiles en el tratamiento de cancer |
| AU2010288502B2 (en) | 2009-08-27 | 2013-12-12 | KaNDy Therapeutics Ltd. | Anhydrate forms of a pyridine derivative |
| WO2011054773A1 (en) | 2009-11-03 | 2011-05-12 | Glaxosmithkline Llc | Novel lactam compounds |
| RS62767B1 (sr) | 2010-04-07 | 2022-01-31 | Vertex Pharma | Farmaceutski sastavi 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiriodin-2-il)benzojeve kiseline i njihova primena |
| JP5815029B2 (ja) | 2010-07-09 | 2015-11-17 | クオンベルゲンセ プハルマセウトイカルス リミテッド | カルシウムチャネル遮断薬としてのテトラゾール化合物 |
| US8648118B2 (en) | 2010-12-17 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Bicyclic ring system substituted amide functionalised phenols as medicaments |
| CN102617503B (zh) * | 2011-03-03 | 2014-05-07 | 上海常丰生物医药科技有限公司 | (s)-3-吗啉基羧酸的合成方法 |
| WO2013049164A1 (en) * | 2011-09-29 | 2013-04-04 | Abbvie Inc. | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS |
| WO2013049174A1 (en) | 2011-09-29 | 2013-04-04 | Abbvie Inc. | Substituted octahydropyrrolo[1,2-a]pyrazine sulfonamides as calcium channel blockers |
| MX355183B (es) | 2012-01-25 | 2018-04-09 | Vertex Pharma | Formulaciones de acido 3- (6- (1- (2.2- difluorobenzo [d] [1,3] dioxol-5-il) ciclopropancarboxamido) -3- metilpiridin-2-il) benzoico. |
| KR20150093237A (ko) | 2012-12-12 | 2015-08-17 | 애브비 인코포레이티드 | 통증 치료시 칼슘 채널 차단제로서 유용한 디아제핀 유도체 |
| BR112016009811A2 (pt) | 2013-11-08 | 2017-12-05 | Kissei Pharmaceutical | derivado de carboximetil piperidina |
| HRP20210516T2 (hr) | 2013-11-12 | 2021-10-01 | Vertex Pharmaceuticals Incorporated | Postupak proizvodnje farmaceutskih pripravaka za liječenje bolesti koje su posredovane putem cftr |
| TWI649307B (zh) | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
| WO2016021562A1 (ja) * | 2014-08-06 | 2016-02-11 | キッセイ薬品工業株式会社 | シアノチオフェン誘導体 |
| KR102576006B1 (ko) | 2014-11-18 | 2023-09-06 | 버텍스 파마슈티칼스 인코포레이티드 | 고처리량 시험 고성능 액체 크로마토그래피의 수행 방법 |
| ES2912881T3 (es) | 2014-12-23 | 2022-05-30 | Convergence Pharmaceuticals | Procedimiento para preparar derivados de alfa-carboxamida pirrolidina |
| HUE047732T2 (hu) * | 2015-05-18 | 2020-05-28 | Nerre Therapeutics Ltd | NK-1/NK-3 receptor antagonista vértolulások kezeléséhez |
| CN112153968A (zh) | 2017-10-05 | 2020-12-29 | 生物基因公司 | 制备α-羧酰胺吡咯烷衍生物的工艺 |
| PL3765024T3 (pl) | 2018-03-14 | 2024-08-05 | KaNDy Therapeutics Limited | <div>Nowa formulacja farmaceutyczna zawierająca podwójnych antagonistów receptora nk-1/nk-3</div> |
| US11583538B2 (en) | 2019-04-08 | 2023-02-21 | Venenum Biodesign, LLC | Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors |
| JP7673064B2 (ja) * | 2019-11-15 | 2025-05-08 | カンディー セラピューティクス リミテッド | Ｎｔ－８１４の重要な中間体である６－クロロ－４－（４－フルオロ－２－メチルフェニル）ピリジン－３－アミンを作製するための新規な化学的方法 |
| WO2021261969A1 (ko) * | 2020-06-26 | 2021-12-30 | 홀로스메딕 주식회사 | 신규한 화합물의 제조방법 |
| KR102682775B1 (ko) * | 2020-06-26 | 2024-07-08 | 홀로스메딕 주식회사 | 신규한 화합물의 제조방법 |
| WO2022075974A1 (en) * | 2020-10-06 | 2022-04-14 | Venenum Biodesign, LLC | Cyclic trex1 inhibitors |
| CA3212755A1 (en) * | 2021-04-05 | 2022-10-13 | Thomas J. Montine | Enantiomer selective action on neurotransmission |
| EP4431512A1 (en) | 2023-03-16 | 2024-09-18 | Bayer Consumer Care AG | Novel dual nk-1/nk-3 receptor antagonists |
| WO2025242585A1 (en) | 2024-05-24 | 2025-11-27 | Bayer Consumer Care Ag | Crystalline forms of salts of elinzanetant and compositions containing salts of elinzanetant |
| WO2025242583A1 (en) | 2024-05-24 | 2025-11-27 | Bayer Consumer Care Ag | Novel formulation comprising elinzanetant in a solid dispersion |
| WO2025242584A1 (en) | 2024-05-24 | 2025-11-27 | Bayer Consumer Care Ag | A stable soft gelatin capsule formulation for elinzanetant |
| TW202604529A (zh) | 2024-06-18 | 2026-02-01 | 瑞士商拜耳保健消費品股份有限公司 | 用於製造依林奈坦(elinzanetant)前驅物之改良方法 |
| US12533358B1 (en) | 2025-05-14 | 2026-01-27 | Bayer Consumer Care Ag | Methods of treatment with elinzanetant |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4921855A (en) | 1987-06-22 | 1990-05-01 | Fujisawa Pharmaceutical Co., Ltd. | New Histidyl amino acid derivatives, and pharmaceutical composition comprising the same |
| US5166203A (en) | 1990-08-30 | 1992-11-24 | Kanebo, Ltd. | Quinolinecarboxylic acid derivatives, antibacterial agent containing the same |
| EP1486498A1 (en) | 1998-11-23 | 2004-12-15 | Pfizer Products Inc. | Process and intermediates for growth hormone secretagogues |
| DK1394150T3 (da) | 1999-02-24 | 2011-03-21 | Hoffmann La Roche | 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister |
| DOP2000000107A (es) | 1999-12-01 | 2002-09-16 | Agouron Pharmaceutical Inc | Compuestos, composiciones y metodos para estimular el crecimiento y alongamiento de las neuronas |
| TWI259180B (en) | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
| GB0203022D0 (en) * | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
| GB0203020D0 (en) * | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
| TW200407324A (en) | 2002-05-17 | 2004-05-16 | Bristol Myers Squibb Co | Bicyclic modulators of androgen receptor function |
| HRP20070471T3 (hr) * | 2003-07-03 | 2007-11-30 | F. Hoffmann - La Roche Ag | Dvojni nk1/nk3 antagonisti za liječenje shizofrenije |
-
2006
- 2006-09-07 US US12/065,923 patent/US7683056B2/en active Active
- 2006-09-07 BR BRPI0615787A patent/BRPI0615787B8/pt active IP Right Grant
- 2006-09-07 SI SI200631047T patent/SI1928886T1/sl unknown
- 2006-09-07 PL PL06777183T patent/PL1928886T3/pl unknown
- 2006-09-07 WO PCT/EP2006/008845 patent/WO2007028654A1/en not_active Ceased
- 2006-09-07 PE PE2006001077A patent/PE20070614A1/es not_active Application Discontinuation
- 2006-09-07 JP JP2008529564A patent/JP5121716B2/ja active Active
- 2006-09-07 EP EP10190918A patent/EP2336136A1/en not_active Withdrawn
- 2006-09-07 CA CA2621564A patent/CA2621564C/en active Active
- 2006-09-07 DK DK06777183.2T patent/DK1928886T3/da active
- 2006-09-07 NZ NZ565983A patent/NZ565983A/en not_active IP Right Cessation
- 2006-09-07 AU AU2006289281A patent/AU2006289281B2/en active Active
- 2006-09-07 AT AT06777183T patent/ATE505472T1/de active
- 2006-09-07 EA EA200800784A patent/EA013909B1/ru unknown
- 2006-09-07 DE DE602006021323T patent/DE602006021323D1/de active Active
- 2006-09-07 AR ARP060103894A patent/AR058805A1/es active IP Right Grant
- 2006-09-07 TW TW095132989A patent/TWI378101B/zh active
- 2006-09-07 HR HR20110457T patent/HRP20110457T1/hr unknown
- 2006-09-07 PT PT06777183T patent/PT1928886E/pt unknown
- 2006-09-07 KR KR1020087008441A patent/KR101292348B1/ko active Active
- 2006-09-07 EP EP06777183A patent/EP1928886B1/en active Active
- 2006-09-07 CN CN2006800418603A patent/CN101305011B/zh active Active
- 2006-09-07 JO JO2006301A patent/JO2722B1/en active
- 2006-09-07 MY MYPI20064110A patent/MY145713A/en unknown
-
2008
- 2008-02-18 IL IL189578A patent/IL189578A/en active IP Right Grant
- 2008-03-17 MA MA30749A patent/MA29780B1/fr unknown
- 2008-03-28 CR CR9847A patent/CR9847A/es not_active Application Discontinuation
- 2008-04-07 NO NO20081728A patent/NO340921B1/no unknown
-
2009
- 2009-12-14 US US12/636,849 patent/US7919491B2/en active Active
-
2011
- 2011-02-23 US US13/032,740 patent/US8097618B2/en active Active
- 2011-07-04 CY CY20111100641T patent/CY1111907T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0615787A2 (pt) | derivados de piridina e seu uso no tratamento de distúrbios psicóticos | |
| ECSP088871A (es) | Derivados de triazolopirazina | |
| AR083070A1 (es) | Analogos de nucleotidos sustituidos con heterociclos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades virales, en particular infecciones por vhc | |
| CY1111720T1 (el) | Αζολο και θειαζολο παραγωγα και η χρηση αυτων | |
| PE20071110A1 (es) | Agentes citotoxicos que comprenden derivados de tomaimicina | |
| PA8558001A1 (es) | Derivados de isonicotin y nicotinamida de benzotiazoles | |
| BRPI0714904A8 (pt) | composições contendo cdp-colina, e seus métodos de uso | |
| CY1109369T1 (el) | Υποκατεστημενες πυρρολοπυριδινες, οι ενωσεις που τις περιεχουν, η διαδικασια παρασκευης τους και η χρηση τους | |
| UY31638A1 (es) | Furo[3,2-c]piridina y tieno[3,2-c]piridinas | |
| HN2009000784A (es) | Dihidropirazolonas sustituidas | |
| ECSP088255A (es) | Derivados de biciclo [2.2.1] hept-7-ilamina y sus usos | |
| AR066492A1 (es) | Derivados de imidazoquinolina, proceso para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de enfermedades virales, bacterianas, alergicas y distintos tipos de canceres. | |
| AR065854A1 (es) | Derivados de 1-oxa-3,9-diaza-espiro[5.5]undecan-2-ona,medicamentos que los contienen y usos como agentes anti vih,entre otros. | |
| BR112013031371A2 (pt) | glicolipídios de cadeias longas úteis para evitar a deterioração ou a contaminação microbiana de materiais | |
| ATE315407T1 (de) | Verbindungen mit einer sulfonamidgruppe und diese verbindungen enthaltende pharmazeutische zusammensetzungen | |
| CY1114669T1 (el) | Υποκατεστημενα παραγωγα σουλφοναμιδιου | |
| BR112014030690A2 (pt) | composições de controle de odores desagradáveis tendo alquenos ativados e seus métodos | |
| PE20080055A1 (es) | Dimeros de derivados de artemisinina y su preparacion | |
| CY1111601T1 (el) | Παραγωγα καρβοξαμιδιων της τριαζολοπυριδινης, η παρασκευη τους και η θεραπευτικη χρηση τους | |
| AR036472A1 (es) | Derivados de azetidina, procedimientos para su preparacion y su empleo como agentes pesticidas | |
| BR0208309A (pt) | Derivados de arilisoxazolina, processos para a sua preparação e sua aplicação como composições praguicidas | |
| DOP2005000218A (es) | Nuevos derivados de aminopiridina que tienen accion inhibitoria selectiva de la aurora a. | |
| ATE510830T1 (de) | Chromen-4-on-derivate als selbstbräunungssubstanz | |
| AR061736A1 (es) | 18- metil-19- nor- androst -4-en -17,17- espiroeteres (18- metil-19-nor-20-espirox-4-en-3-onas) , asi como preparaciones farmaceuticas que los contienen | |
| AR042967A1 (es) | Derivados de amino avermectina monosacarido sustituidos en la posicion 4' que tienen propiedades plaguicidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: GLAXOSMITHKLINE LLC (US) Free format text: NOME ALTERADO DE: SMITHKLINE BEECHAM CORPORATION |
|
| B25C | Requirement related to requested transfer of rights |
Owner name: GLAXOSMITHKLINE LLC (US) Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 20130082870/RJ DE 15/10/2013, E NECESSARIO APRESENTAR O DOCUMENTO DE TRANSFERENCIA COM A DEVIDA LEGALIZACAO CONSULAR. |
|
| B25A | Requested transfer of rights approved |
Owner name: NERRE THERAPEUTICS LIMITED (GB) |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/08/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/09/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B25A | Requested transfer of rights approved |
Owner name: KANDY THERAPEUTICS LIMITED (GB) |